ArticleFrontiers in neurology
Diabetes-duration-related shifts in inflammation-resolving lipid mediator signatures and their association with 3-month functional outcome in large artery atherosclerotic stroke.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Specialized pro-resolving lipid mediators are involved in post-stroke neuroinflammation, but their relevance in large artery atherosclerotic (LAA) stroke, particularly in relation to diabetes duration, remains unclear. Methods: In this single-center retrospective study, 175 patients with LAA stroke were enrolled. Serum lipoxin A4 (LXA4), leukotriene B4 (LTB4), and resolvin D2 (RvD2) were measured within 72 h of stroke onset. Functional outcome at 3 months was assessed using the modified Rankin Scale. Analyses were stratified by type 2 diabetes mellitus (T2DM) status and diabetes duration (<5 vs. ≥5 years). Logistic regression and linear support vector machine models were used in exploratory analyses. Results: Of the 175 patients, 130 had a favorable outcome and 45 a poor outcome. LXA4 levels were higher in the favorable-outcome group, although the difference was not significant. No significant differences in LXA4, LTB4, or RvD2 were observed between patients with and without T2DM. In contrast, within the T2DM subgroup, patients with a diabetes duration of ≥5 years showed higher LXA4 and LTB4 levels and a lower RvD2/LTB4 ratio than those with a duration of <5 years. Diabetes duration correlated positively with both LXA4 and LTB4. In exploratory machine learning analyses, LXA4 was consistently retained, and model performance declined after its removal. Conclusion: These findings are exploratory. LAA stroke was associated with diabetes duration-related remodeling of specialized pro-resolving lipid mediator profiles. Compared with diabetes status alone, diabetes duration may better reflect metabolic-inflammatory heterogeneity. These findings are exploratory; LXA4 did not demonstrate a statistically significant association with functional outcome, and no independent prognostic value has been established. LXA4 may represent a candidate signaling molecule warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.